Mirabegron Zentiva (Mirabegron)

Mirabegron selectively stimulates β3‑adrenergic receptors in the detrusor muscle of the bladder. This activation relaxes the muscle during the storage phase, allowing the bladder to hold more urine and decreasing the frequency of sudden urges to void.

The prescribed dose is determined by the treating clinician based on the patient’s condition and response. A common starting regimen is 25 mg taken once daily, which may be increased to 50 mg once daily if needed, but exact dosing must follow the prescriber’s instructions.

Safety data for Mirabegron in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the Mirabegron Zentiva product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirabegron belongs to a different class (β3‑adrenergic agonist) and does not have the anticholinergic side‑effects such as dry mouth and constipation that are common with antimuscarinic agents. It may be used alone or in combination with antimuscarinics to enhance symptom control while offering an alternative safety profile.

Store the tablets at ambient temperature, preferably below 25 °C (77 °F). Keep them in the original packaging, protect from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Mirabegron Zentiva is taken orally as a whole tablet with or without food. The tablet should be swallowed whole with a glass of water and taken at the same time each day to maintain consistent blood levels.

Serious adverse events include severe hypertension, tachycardia, angioedema, urinary retention, and rare cases of myocardial infarction. Patients should be monitored for significant increases in blood pressure or heart rate and advised to seek medical attention if these occur.

Mirabegron is contraindicated in patients with uncontrolled hypertension, severe hepatic impairment, or known hypersensitivity to mirabegron or any tablet excipients. Caution is also advised for individuals taking strong CYP2D6 inhibitors or those with significant cardiovascular disease.